Cancer Advisor

Abstract Background:  Stage IV pancreatic ductal adenocarcinoma (PDAC) lacking actionable mutations has limited treatment options, with median overall survival (mOS) of 9–11 months using standard chemotherapy. Repurposed drugs (ivermectin, mebendazole) and hyperthermia show preclinical promise. This in silico randomized controlled trial (RCT) evaluates an integrative protocol combining ivermectin, mebendazole, hyperthermia, supplements, and lifestyle interventions versus standard-of-care (SOC) NALIRIFOX chemotherapy in non-BRCA-mutated stage IV PDAC. Methods:  A simulated two-arm RCT enrolled 200 patients with non-BRCA-mutated stage IV PDAC, randomized 1:1 to an experimental arm (ivermectin 1 mg/kg/day 3 days/week, mebendazole 500 mg twice daily, localized hyperthermia 42–43°C 3 sessions/week, supplements [vitamin C, vitamin D, curcumin, berberine], ketogenic diet, intermittent fasting, pancreatic enzymes) or control arm (NALIRIFOX). Primary endpoint was 12-month overall surv...

In a revealing post on X (formerly Twitter), whistleblower account @Jikkyleaks has shed light on four prominent universities that have quietly pursued patents and research on anti-parasitic medications—such as ivermectin, mebendazole, and fenbendazole—for treating various cancers. These drugs, long used to combat parasites in humans and animals, are now being explored for their potential anticancer properties.  The post, which credits AI assistant Grok for verifying the details, questions why this potentially game-changing information hasn't been more publicly disseminated. Drawing from the post and its sources, this article explores the universities involved, the science behind the drugs, and the broader implications. The Universities and Their Patent Pursuits According to the information compiled in the post, these institutions have been actively involved in patenting or researching these repurposed drugs. Here's a breakdown: University of British Columbia (UBC) The Universi...

Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146  (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balstilimab in patients wit...

Executive Summary Cancer immunotherapy represents one of the most consequential paradigm shifts in oncology since the advent of combination chemotherapy [1–3]. By targeting immune checkpoints, tumor antigens, or immune effector cells themselves, immunotherapies have delivered durable, and in some cases curative, responses in a subset of patients across historically lethal malignancies [4–7]. However, population-level benefit remains heterogeneous. Immune checkpoint inhibitors (ICIs) consistently extend survival in several cancers, although absolute overall survival (OS) gains are often modest at a population level . Many regulatory approvals rely on surrogate endpoints rather than mature overall survival (OS) data [32,35], immune-related toxicities can be severe or permanent [28–30], and costs place substantial strain on healthcare systems [38–40]. Real-world effectiveness frequently diverges from pivotal trial results [54]. Credit:  Statista 1. Introduction 1.1 Historical Context...